Alfred Chung

96 posts

Alfred Chung

Alfred Chung

@AlfredChung11

Hematologist @UCSFCancer- myeloma/amyloidosis ; Alum: @StanfordCancer @StanfordMedRes @NUFeinbergMed @Umich

Katılım Ocak 2019
284 Takip Edilen300 Takipçiler
Alfred Chung retweetledi
Rahul Banerjee, MD, FACP
Rahul Banerjee, MD, FACP@RahulBanerjeeMD·
Awesome job by @UCSFCancer @Kevin_Reyes650 med student extraordinaire and senior author @AlfredChung11 on this paper - #ASH22 updated data from #IMS22. In short, old lines (including Tx disease was once refractory to) are reasonable to recycle after BCMA CAR-T failure!
Muzaffar Qazilbash@Transplant_Doc

#ASH22 Clinical Outcomes and Salvage Rx in RRMM Following PD on anti-BCMA CAR-T Rx. N=42, median OS 14.8 months #mmsm #bmtsm @AlfredChung11 @RahulBanerjeeMD @SandyWong02111 @ninashah33 @TomBmt133 ash.confex.com/ash/2022/webpr…

English
0
5
13
0
Alfred Chung retweetledi
Rahul Banerjee, MD, FACP
Rahul Banerjee, MD, FACP@RahulBanerjeeMD·
So so proud of Kevin Reyes, med student at @UCSFMedicine, for presenting an #IMS22 oral! (Actually two 😉, 2nd one tomorrow) @UCSFCancer experience with post-BCMA CAR-T relapse. Bottom line - we probably don’t re-challenge #MMsm with previously used drugs as often as we could!
Rahul Banerjee, MD, FACP tweet mediaRahul Banerjee, MD, FACP tweet mediaRahul Banerjee, MD, FACP tweet media
Los Angeles, CA 🇺🇸 English
2
8
34
0
Alfred Chung
Alfred Chung@AlfredChung11·
@bdermanmd May or may not be related but I have seen couple cases of rapid choroidal effusion buildup/acute bilateral angle closure presentation in setting of receiving 1st dose of daratumumab. Unclear if can retrial- this case report suggest can w/ ppx cycloplegics sciencedirect.com/science/articl…
English
0
0
1
0
Alfred Chung
Alfred Chung@AlfredChung11·
@ninashah33 Possibly an option in patients with CNS disease - case reports of CNS lymphoma responding and preclinical data to suggest good CNS penetration of selinexor. Aside from Len/pom, not that many CNS active agents xcept hopefully BCMA CART
English
0
0
5
0
Nina Shah
Nina Shah@ninashah33·
Need for SPeeD! Selinexor Pom Dex ORR 60% at RP2D PFS 12 mo. This looks good but I think the real phase III should be SPD vs KPD. Who’s ready to fund this ? #mmsm #ASH20
Nina Shah tweet mediaNina Shah tweet mediaNina Shah tweet mediaNina Shah tweet media
English
3
6
32
0
Alfred Chung
Alfred Chung@AlfredChung11·
@bdermanmd More data to suggest MRD assessments over time is important. Losing MRD-neg probably stronger marker of developing tx resistance
English
0
0
0
0
Ben Derman
Ben Derman@bdermanmd·
MRD in myeloma is not like love. With maintenance, it seems it is better to have never achieved MRD-neg than to have achieved it and lost!? #mmMRD #ASH20
Ben Derman tweet media
Ben Diamond, MD@BenDiamondMD

Stop by for a listen to our data on sustained MRD-negativity for len maintenance in #myeloma. No progression events seen after 2 years sustained negativity. When should we cease maintenance? Recording ID 1369. #ASH20 @LesokhinMD @DrOlaLandgren @MSKCC ash.confex.com/ash/2020/webpr…

English
2
1
8
0
Alfred Chung
Alfred Chung@AlfredChung11·
The nailBiTEing BCMA bispecific race (slide courtesy Dr. Chari)! #ASH20 #mmsm
Alfred Chung tweet media
English
1
16
63
0
Alfred Chung
Alfred Chung@AlfredChung11·
Aside from CD19 being target on myeloma, I wonder about the role of CD19 being present more ubiquitously on normal/developing B-cells: will this lead to more CAR-T persistence or exhaustion due to tonic signaling?
Nina Shah@ninashah33

#myeloma in the FAST LANE! BCMA & CD19 targeting CAR with Fast CAR T platform. 94%ORR with all evaluable pts MRD neg. 24-36 h mfg time !! #mmsm #ASH20

English
0
0
7
0
Alfred Chung
Alfred Chung@AlfredChung11·
@bdermanmd @rajshekharucms I can see several poss.: 1)R2 selects for pts proven to be CFZ sens 2)10^-5 not deep enough for true MRD- 3)2 drugs > 1 Does show MRD- at single time pt is tricky; evidence that “de-escal” after MRD- may be more nuanced (KR>R despite MRD-). But still prognostic
English
0
0
1
0
Ben Derman
Ben Derman@bdermanmd·
To add on (h/t @rajshekharucms): Not all MRD-negative patients behaved the same. KR MRD-neg patients had superior PFS to 'R' MRD-neg patients. #mmMRD
Ben Derman tweet media
English
4
3
7
0
Ben Derman
Ben Derman@bdermanmd·
Dr. Gay presenting great data from FORTE trial. Shows that patients who received KR in maintenance arm achieved higher rates of MRD-neg(10^-5) & superior PFS compared to R alone. Also: high risk patients who reach MRD-neg seem to have similar outcomes to std-risk MRD-neg #mmMRD
Ben Derman tweet mediaBen Derman tweet media
English
5
11
24
0
Alfred Chung
Alfred Chung@AlfredChung11·
@AaronGoodman33 Agree with this - we need MRD adapted trials to answer those questions. But it could be another data point in context with whole clinical picture
English
0
0
0
0
Alfred Chung
Alfred Chung@AlfredChung11·
@AaronGoodman33 Agree heterogeneity of data makes it hard to use. 3 reasons to test: 1) as prog marker 2) enroll in trials for MRD+pts (eg AURIGA) 3) add data point in clin decis making. Controversial, but most medicine based on utilizing empiric data as a whole Whether worth the $ is another ?
English
0
0
2
0
Alfred Chung
Alfred Chung@AlfredChung11·
@rajshekharucms @ASCO_pubs Probably get more bang for the buck with adding dara instead of cytoxan for these patients; works fasts and avoids potentially unnecessary alkylator toxicity
English
2
0
4
0
Raj Chakraborty
Raj Chakraborty@rajshekharucms·
Interesting RCT showing that CyBorD no better than Vd in #MultipleMyeloma presenting with AKI. Makes one wonder whether cytoxan adds anything in Dara-CyBorD for AL amyloidosis as well #mmsm @ASCO_pubs
Luciano J Costa@End_myeloma

Randomized Vd vs VCd in MM and AKI Due to Cast Nephropathy | Journal of Clinical Oncology. Not Sexy, but super helpful. Congratulations in performing a rand trial in an often neglected population. #mmsm ascopubs.org/doi/abs/10.120…

English
3
1
13
0

Keşfet

@UCSFCancer @Kevin_Reyes650 @rajshekharucms @CAMPamyloidosis @SLentzsch @columbiacancer @RahulBanerjeeMD @UCSFMedicine